Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 9/20 | 0.52 |
| ▸ | LIPG | Q9Y5X9 | 9/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22683555 | 0.83 | ESR1 (0.50) | LPLLIPGCA2CA1ENPP2 | |
| SCHEMBL3786850 | 0.83 | LPL (0.48) | LPLLIPGCA2CA1ENPP2 | |
| SCHEMBL12832676 | 0.83 | LPL (0.48) | LPLLIPGCA2CA1ENPP2 | |
| SCHEMBL3186771 | 0.81 | LPL (0.47) | LPLLIPGCA2CA1ENPP2 | |
| SCHEMBL2413286 | 0.81 | LPL (0.47) | LPLLIPGCA2CA1ENPP2 | |
| SCHEMBL17485375 | 0.81 | LPL (0.47) | LPLLIPGCA2CA1ENPP2 | |
| SCHEMBL3082470 | 0.81 | LPL (0.47) | LPLLIPGCA2CA1ENPP2 | |
| SCHEMBL29953894 | 0.81 | LPL (0.47) | LPLLIPGCA2CA1ENPP2 | |
| SCHEMBL15542487 | 0.79 | LPL (0.45) | LPLLIPGCA2CA1ENPP2 | |
| SCHEMBL23177322 | 0.79 | LPL (0.38) | LPLLIPGCA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
| WO-2000026173-A1 | NOVEL RETINOIDS, METHODS FOR THEIR PRODUCTION AND USE | LIGAND PHARMACEUTICALS INCORPORATED (DE) | 2000-05-11 | — | — | WO | disclosed |
| US-6005007-A | SKIN DISORDERS | LIGAND PHARMACEUTICALS INCORPORATED | 1999-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | LPL 3816/4885LIPG 3010/4885CA2 1992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.